Overview

A Phase II Study of Minocycline and Armodafinil for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Esophageal Cancer

Status:
Completed

Trial end date:
2017-01-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is to compare armodafinil and minocycline when given alone or in combination to learn which is better for controlling side effects of chemoradiation treatment for esophageal cancer (such as fatigue, pain, disturbed sleep, lack of appetite, and drowsiness). Armodafinil is designed to prevent excessive sleepiness. Minocycline is an antibiotic, which may help to reduce multiple symptoms. In this study, you may receive a placebo. A placebo is not a drug. It looks like the study drug but is not designed to treat any disease or illness. It is designed to be compared with a study drug to learn if the study drug has any real effect.

Phase:

Phase 2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

National Cancer Institute (NCI)

Treatments:

Armodafinil
Minocycline
Modafinil